Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasia
Conditions
Interventions
Azacitidine
Entinostat
+1 more
Locations
234
United States
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, United States
Los Angeles Oncology Institute
Los Angeles, California, United States
Stanford Cancer Institute
Palo Alto, California, United States
Sutter Roseville Medical Center
Roseville, California, United States
Sutter General Hospital
Sacramento, California, United States
Start Date
August 1, 2006
Primary Completion Date
July 1, 2013
Completion Date
July 1, 2013
Last Updated
February 2, 2017
NCT03874052
NCT03128034
NCT04284787
NCT04190550
NCT04269213
NCT03330821
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions